Interpace Diagnostics Group (IDXG) Announces Earnings Results, Misses Expectations By $0.04 EPS

Interpace Diagnostics Group (NASDAQ:IDXG) issued its earnings results on Tuesday. The business services provider reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.04), Morningstar.com reports. The firm had revenue of $5.75 million during the quarter, compared to analysts’ expectations of $5.50 million. Interpace Diagnostics Group had a negative net margin of 71.14% and a negative return on equity of 34.58%.

Interpace Diagnostics Group stock traded down $0.26 during mid-day trading on Wednesday, hitting $1.20. The company had a trading volume of 36,322 shares, compared to its average volume of 243,353. Interpace Diagnostics Group has a 12-month low of $0.77 and a 12-month high of $1.78. The firm has a market cap of $41.75 million, a PE ratio of -1.47 and a beta of 2.26.

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $172,000. JPMorgan Chase & Co. purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $194,000. Essex Investment Management Co. LLC purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $465,000. Finally, Perkins Capital Management Inc. purchased a new stake in Interpace Diagnostics Group in the 3rd quarter worth approximately $983,000. Institutional investors and hedge funds own 15.55% of the company’s stock.

IDXG has been the topic of a number of recent research reports. HC Wainwright set a $3.00 target price on Interpace Diagnostics Group and gave the company a “buy” rating in a research report on Friday, August 10th. Maxim Group reiterated a “buy” rating and issued a $3.00 target price on shares of Interpace Diagnostics Group in a research report on Friday, August 10th. Zacks Investment Research upgraded Interpace Diagnostics Group from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Wednesday, August 22nd. Finally, Dawson James initiated coverage on Interpace Diagnostics Group in a research report on Wednesday, October 17th. They issued a “buy” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $3.17.

TRADEMARK VIOLATION WARNING: This article was published by WKRB News and is owned by of WKRB News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.wkrb13.com/2018/11/14/interpace-diagnostics-group-idxg-announces-earnings-results-misses-expectations-by-0-04-eps.html.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Earnings History for Interpace Diagnostics Group (NASDAQ:IDXG)

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply